Skip to main navigation Skip to search Skip to main content

Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts

  • Faizal Z. Asumda
  • , Nellie A. Campbell
  • , Mohamed A. Hassan
  • , Reza Fathi
  • , Daniella F. Vasquez Rico
  • , Melanie Kiem
  • , Ethan V. Vang
  • , Yo Han Kim
  • , Xin Luo
  • , Daniel R. O’Brien
  • , Sarah A. Buhrow
  • , Joel M. Reid
  • , Michael J. Moore
  • , Vered Katz Ben-Yair
  • , Mark L. Levitt
  • , Jennifer L. Leiting
  • , Amro M. Abdelrahman
  • , Xinli Zhu
  • , Fabrice Lucien
  • , Mark J. Truty
  • Lewis R. Roberts

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science